This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Haemophagocytic lymphohistiocytosis혈구탐식성 림프조직구증

ICD-10: D76.1 | Synonyms: HLH, Hemophagocytic syndrome, Macrophage activation syndrome (MAS)

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description and naming

Hemophagocytic lymphohistiocytosis (HLH) was first described in 1952 by Scott and Robb-Smith. They described a pathological syndrome with a fatal course accompanied by histiocytic proliferation and hemophagocytosis as "histiocytic medullary reticulosis." Later, in 1979, Farquhar and Claireaux described a fatal histiocytosis occurring in siblings and proposed the name "familial haemophagocytic reticulosis (FHL)."

Establishment of the modern concept

In the 1980s–1990s, many cases of secondary HLH associated with infection, autoimmune disease, and malignancy were reported, and HLH came to be recognized as a clinical syndrome of immune dysregulation rather than a simple genetic disease. In 1991, the Histiocyte Society first proposed diagnostic criteria for HLH, and in 1994 the HLH-94 protocol was established, setting a standard treatment centered on dexamethasone and etoposide.

History of HLH research in Korea

In Korea, pediatric HLH cases began to be systematically reported in the late 1990s. Since the 2000s, as awareness of adult HLH has grown, multidisciplinary collaboration across hematology-oncology, pediatrics, rheumatology, infectious diseases, and other departments has been strengthened.

2. Causes

Primary (hereditary) HLH

Primary HLH is caused by mutations in genes involved in the cytotoxic function of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. Representative causative genes include perforin (PRF1), MUNC13-4 (UNC13D), Syntaxin 11 (STX11), MUNC18-2 (STXBP2), and RAB27A; variants in these genes block the secretory pathway of lytic granules, so CTL and NK cells lose their ability to kill target cells. Most primary HLH follows an autosomal recessive mode of inheritance.

Secondary (acquired) HLH

The main causes of secondary HLH are as follows. Infectious: Epstein-Barr virus (EBV) is the most common; cytomegalovirus (CMV), influenza, HIV, Mycobacterium tuberculosis, and others are also causes. Autoimmune/autoinflammatory: presents as giant cell activation syndrome (MAS) accompanying systemic juvenile idiopathic arthritis (sJIA), systemic lupus erythematosus (SLE), adult-onset Still's disease, and others. Malignancy: occurs as a complication of T-cell lymphoma, NK-cell lymphoma, acute leukemia, and others.

3. Genetics

Major genes and mode of inheritance

The genetic causes of primary HLH are broadly classified into two groups. Among the familial types classified as FHL1–5, FHL2 is caused by mutations in the PRF1 (perforin 1) gene (10q22), FHL3 by mutations in the UNC13D gene (17q25), FHL4 by mutations in the STX11 (6q24) gene, and FHL5 by mutations in the STXBP2 (19p13) gene. All of these follow an autosomal recessive mode of inheritance. HLH associated with immunodeficiency syndromes includes Chediak-Higashi syndrome (LYST gene), Griscelli syndrome type 2 (RAB27A gene), Hermansky-Pudlak syndrome type 2 (AP3B1 gene), and others.

Genotype-phenotype correlation

PRF1 mutations (FHL2) account for about 30–50% of all primary HLH, and the p.A91V polymorphism in particular may act as a predisposition to HLH in adults. UNC13D mutations (FHL3) are reported relatively frequently in East Asian populations, including Korea, Japan, and China. In those with compound heterozygous mutations, the phenotype can vary.

4. General epidemiology

Worldwide incidence

HLH is a rare disease; the incidence of primary HLH is estimated at about 1–2 per million newborns. A survey in Sweden found a pediatric HLH incidence of about 1.2 per million children per year. Secondary HLH occurs more frequently in ICU patients, immunosuppressed patients, and patients with hematologic malignancies.

Age and sex distribution

Primary HLH mainly develops in infants and children, with more than 80% presenting within the first year of life. However, it has also been reported in adults, and adult HLH is mostly due to secondary causes (infection, malignancy, autoimmunity). There is no clear sex difference.

Situation in Korea

In Korea, a substantial proportion of pediatric HLH patients are associated with EBV infection, consistent with the high frequency of EBV-associated HLH in East Asia. Adult HLH is also mainly associated with EBV and hematologic malignancies, and dozens of new diagnoses per year are reported at Korean university hospitals.

5. Pathophysiology

Defective cytotoxic function and immune dysregulation

Normally, CTL and NK cells kill target cells (virus-infected cells, tumor cells) by secreting lytic granules containing perforin and granzymes into the immunological synapse with the target cell. In HLH this process is blocked, so target cells are not killed, and the interaction between antigen-presenting cells (APC) and T cells is persistently maintained.

Development of the cytokine storm

Because of defective cytotoxic function, activated T cells and macrophages proliferate excessively, and large amounts of inflammatory cytokines such as IFN-γ, TNF-α, IL-6, IL-10, IL-12, and IL-18 are secreted. IFN-γ in particular is the key mediator of macrophage activation; activated macrophages form a positive feedback cycle through hemophagocytosis and further cytokine secretion. This "cytokine storm" is the core mechanism of multiorgan failure.

Hemophagocytosis

Activated histiocytes/macrophages phagocytose blood cells, including red blood cells, white blood cells, and platelets, in the bone marrow, spleen, and lymph nodes, causing pancytopenia. This is the key pathological finding from which the disease takes its name.

6. Symptoms

Fever

Persistent high fever (38.5℃ or higher) is the earliest and most common symptom of HLH; fever lasting days to weeks that does not respond to antibiotics is characteristic.

Symptoms related to cytopenias

Pancytopenia causes pallor, fatigue, and a bleeding tendency (petechiae, ecchymoses, epistaxis, gastrointestinal bleeding). Susceptibility to infection increases, and secondary infections may occur.

Splenomegaly and lymphadenopathy

Splenomegaly is a key symptom of HLH and is sometimes accompanied by tenderness. Lymphadenopathy is also commonly observed.

Neurological symptoms

In primary HLH and some secondary HLH, seizures, altered consciousness, meningeal irritation, and symptoms of raised intracranial pressure may occur. Nervous system involvement is an important factor that worsens prognosis.

7. Signs

Physical examination findings

On physical examination, splenomegaly (splenic tip 3 cm or more below the costal margin) and hepatomegaly are the main signs. Along with fever, lymphadenopathy, skin rash, and jaundice may be present. With nervous system involvement, neck stiffness, decreased consciousness, and focal neurological deficits may occur.

Laboratory findings

Test itemFindingsReference value
Hemoglobin (Hb)Decreased<9 g/dL
PlateletsDecreased<100×10³/μL
NeutrophilsDecreased<1×10³/μL
Serum ferritinMarkedly elevated>500 ng/mL (often >10,000)
TriglyceridesElevated≥3.0 mmol/L
FibrinogenDecreased<1.5 g/L
Soluble CD25Markedly elevated≥2,400 U/mL
NK cell activityDecreased or absent—

Bone marrow and imaging findings

Bone marrow aspiration and biopsy show hemophagocytosis by histiocytes. Abdominal ultrasound or CT may show hepatosplenomegaly and ascites. On brain MRI, T2 hyperintense lesions and ventricular enlargement may be evidence of nervous system involvement.

8. Screening

Use of the HScore

The HScore is a clinical tool that scores the likelihood of HLH; it sums 9 items—fever, splenomegaly, cytopenias, ferritin, triglycerides, fibrinogen, bone marrow hemophagocytosis, AST, and underlying immunodeficiency—to calculate the probability of HLH. A score of 169 or higher is reported to correspond to a 93% probability of HLH.

Use of serum ferritin for screening

Serum ferritin >500 ng/mL is a nonspecific screening marker for HLH, whereas >10,000 ng/mL is highly specific for HLH. In ICU patients and patients with fever of unknown origin, an unexplained extreme rise in ferritin should raise strong suspicion of HLH.

Screening of high-risk groups

Perform HLH screening tests immediately when there is a family history of primary HLH, when an infant has fever with pancytopenia, or when the clinical condition deteriorates rapidly after EBV infection.

9. Diagnosis

HLH-2004 diagnostic criteria

According to the Histiocyte Society HLH-2004 criteria, HLH is diagnosed when 5 or more of the following 8 items are met or when a molecular genetic diagnosis is confirmed.

  1. Fever (38.5℃ or higher)
  2. Splenomegaly
  3. Cytopenias (2 or more lineages: Hb<9 g/dL, platelets<100×10³/μL, neutrophils<1×10³/μL)
  4. Hypertriglyceridemia (≥3.0 mmol/L) or hypofibrinogenemia (<1.5 g/L)
  5. Hemophagocytosis in bone marrow, spleen, or lymph node tissue
  6. Decreased or absent NK cell activity
  7. Serum ferritin ≥500 ng/mL
  8. Serum soluble CD25 (sIL-2R) ≥2,400 U/mL

Molecular genetic diagnosis

NGS panel testing of HLH-related genes such as PRF1, UNC13D, STX11, and STXBP2. Flow cytometry to confirm perforin protein expression. Diagnosis is confirmed when a primary HLH gene mutation is identified.

Tests to identify the cause

Viral testing for EBV, CMV, HSV, HIV, and others (PCR, serology). Autoimmune antibody testing (ANA, anti-dsDNA, RF, etc.). Bone marrow biopsy and lymph node biopsy to exclude malignancy.

10. Treatment

HLH-94/2004 standard treatment protocol

The standard treatment for primary and severe secondary HLH is the HLH-94/2004 protocol, consisting of 8 weeks of induction therapy. It is based on dexamethasone (high dose, tapering regimen) and etoposide (VP-16, twice weekly → once weekly), with intrathecal methotrexate (IT-MTX) added when the central nervous system is involved.

Curative treatment of primary HLH

The only curative treatment for primary HLH is allogeneic hematopoietic stem cell transplantation (allo-HSCT). If no HLA-matched sibling donor is available, an unrelated donor or haploidentical transplant is performed. Reduced-intensity conditioning (RIC) transplantation is reported to reduce the toxicity of standard transplantation while being equally effective.

Treatment of secondary HLH

Treating the underlying disease is central in secondary HLH. For EBV-associated HLH, EBV antiviral treatment is considered along with the HLH-94/2004 protocol. For MAS (giant cell activation syndrome), high-dose steroids, cyclosporine, anakinra (an IL-1 receptor antagonist), and similar agents are used first.

New targeted therapies

The IFN-γ monoclonal antibody emapalumab received US FDA approval (2018) for primary HLH and is used for primary HLH that is refractory to or relapses after conventional therapy. The JAK1/2 inhibitor ruxolitinib is also under clinical investigation.

11. Prognosis

Without treatment

Without treatment, HLH is fatal in almost all cases, with a reported median survival of less than 2 months. Multiorgan failure, bleeding, and central nervous system involvement are the direct causes of death.

Prognosis with treatment

With the HLH-94/2004 protocol, the 5-year survival rate is reported to be about 54–64%. The 5-year survival rate after hematopoietic stem cell transplantation for primary HLH is about 60–70%. Central nervous system involvement, delayed diagnosis, and incomplete response to induction therapy are poor prognostic factors.

Prognostic factors

Serum ferritin level at diagnosis, central nervous system involvement, EBV viral load, and response to initial treatment are the key factors determining prognosis.

12. Prevention

Genetic counseling and family screening

Genetic testing is performed in family members (especially siblings) of patients with primary HLH to identify early whether they carry the same mutation or are affected. Thorough genetic counseling for carrier parents and prenatal diagnosis in subsequent pregnancies are recommended.

Prevention of secondary HLH

In immunosuppressed patients after transplantation, monitor for viruses such as EBV and CMV and provide prophylactic antiviral therapy. In patients with autoimmune diseases, recognize prodromal symptoms of MAS (sudden fever, rapid rise in ferritin) early and intensify treatment.

Importance of early diagnosis

The prognosis of HLH depends greatly on the timing of diagnosis and treatment initiation. HLH should be included early in the differential diagnosis of any patient with a combination of fever of unknown origin, cytopenias, splenomegaly, and hyperferritinemia.

13. References

  1. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
  2. Janka GE. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin Padiatr. 2009;221(5):278-285.
  3. Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009:127-131.
  4. Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728-2738.
  5. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332-1343.
  6. Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929.
  7. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
  8. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.
  9. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.
  10. Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Ann Rheum Dis. 2016;75(3):481-489.
  11. Kim HJ, Lee JW, Kim NH, et al. Hemophagocytic lymphohistiocytosis in Korean children: clinical features, genetic basis, and treatment outcome. Blood Res. 2019;54(1):45-52.
  12. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.